Clearside Biomedical (CLSD) Stock Forecast, Price & News

Clearside Biomedical (NASDAQ:CLSD) Frequently Asked Questions

Is Clearside Biomedical a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clearside Biomedical in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Clearside Biomedical stock.
View analyst ratings for Clearside Biomedical or view top-rated stocks.

When is Clearside Biomedical's next earnings date?

Clearside Biomedical is scheduled to release its next quarterly earnings announcement on Tuesday, August 9th 2022.
View our earnings forecast for Clearside Biomedical.

How were Clearside Biomedical's earnings last quarter?

Clearside Biomedical, Inc. (NASDAQ:CLSD) released its quarterly earnings data on Wednesday, May, 11th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by $0.10. Clearside Biomedical had a trailing twelve-month return on equity of 0.31% and a net margin of 0.28%. During the same quarter in the previous year, the business posted ($0.13) EPS.
View Clearside Biomedical's earnings history.

What price target have analysts set for CLSD?

4 analysts have issued 12 month price targets for Clearside Biomedical's stock. Their forecasts range from $9.00 to $15.00. On average, they anticipate Clearside Biomedical's share price to reach $11.00 in the next twelve months. This suggests a possible upside of 697.1% from the stock's current price.
View analysts' price targets for Clearside Biomedical or view top-rated stocks among Wall Street analysts.

Who are Clearside Biomedical's key executives?

Clearside Biomedical's management team includes the following people:

• Dr. George M. Lasezkay Pharm.D., Pharma.D., J.D., Pres, CEO & Director (Age 70, Pay $681.67k)
• Mr. Charles A. Deignan, Chief Financial Officer (Age 58, Pay $430.33k) (LinkedIn Profile)
• Dr. Thomas A. Ciulla M.B.A., M.D., Chief Medical Officer & Chief Devel. Officer
• Ms. Jenny R. Kobin, Head of Investor Relations (Age 55)
• Mr. Leslie B. Zacks, Gen. Counsel, Chief Compliance Officer & Sec. (Age 53)
• Mr. Rick McElheny, VP of Corp. Devel.

Who are some of Clearside Biomedical's key competitors?

Some companies that are related to Clearside Biomedical include Arbutus Biopharma (ABUS), Fulcrum Therapeutics (FULC), Edgewise Therapeutics (EWTX), Zymeworks (ZYME), Khosla Ventures Acquisition (KVSA), Phathom Pharmaceuticals (PHAT), Mersana Therapeutics (MRSN), Kezar Life Sciences (KZR), Seres Therapeutics (MCRB), Aerovate Therapeutics (AVTE), Enochian Biosciences (ENOB), Akero Therapeutics (AKRO), Thorne HealthTech (THRN), Aadi Bioscience (AADI) and InterCure (INCR).
View all of CLSD's competitors.

What other stocks do shareholders of Clearside Biomedical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Clearside Biomedical investors own include Northwest Biotherapeutics (NWBO), Ocular Therapeutix (OCUL), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Melinta Therapeutics (MLNT), OrganiGram (OGI), Zosano Pharma (ZSAN), Sorrento Therapeutics (SRNE), Miragen Therapeutics (MGEN) and Gran Tierra Energy (GTE).

When did Clearside Biomedical IPO?

(CLSD) raised $50 million in an initial public offering on Thursday, June 2nd 2016. The company issued 7,200,000 shares at $7.00 per share. Cowen and Company and Stifel served as the underwriters for the IPO and Needham & Company, Wedbush PacGrow was co-manager.

What is Clearside Biomedical's stock symbol?

Clearside Biomedical trades on the NASDAQ under the ticker symbol "CLSD."

Who are Clearside Biomedical's major shareholders?

Clearside Biomedical's stock is owned by many different retail and institutional investors. Top institutional shareholders include Carmignac Gestion (4.13%), ACT Capital Management LLC (4.09%), Vanguard Group Inc. (3.60%), Assenagon Asset Management S.A. (1.52%), Renaissance Technologies LLC (1.44%) and State Street Corp (0.32%). Company insiders that own Clearside Biomedical stock include Bradford T Whitmore, Bradford T Whitmore, Charles A Deignan, Clay Thorp, George M Lasezkay, George M Lasezkay, Richard T Burke, Thomas Ciulla and William D Humphries.
View institutional ownership trends for Clearside Biomedical.

Which major investors are selling Clearside Biomedical stock?

CLSD stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Carmignac Gestion, Group One Trading L.P., Goldman Sachs Group Inc., ACT Capital Management LLC, Principal Financial Group Inc., HAP Trading LLC, and Vanguard Group Inc.. Company insiders that have sold Clearside Biomedical company stock in the last year include Bradford T Whitmore, Charles A Deignan, George M Lasezkay, Richard T Burke, and Thomas Ciulla.
View insider buying and selling activity for Clearside Biomedical or view top insider-selling stocks.

Which major investors are buying Clearside Biomedical stock?

CLSD stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Connor Clark & Lunn Investment Management Ltd., GSA Capital Partners LLP, Jane Street Group LLC, Synovus Financial Corp, XTX Topco Ltd, Simplex Trading LLC, and Bailard Inc.. Company insiders that have bought Clearside Biomedical stock in the last two years include Bradford T Whitmore, and William D Humphries.
View insider buying and selling activity for Clearside Biomedical or or view top insider-buying stocks.

How do I buy shares of Clearside Biomedical?

Shares of CLSD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Clearside Biomedical's stock price today?

One share of CLSD stock can currently be purchased for approximately $1.38.

How much money does Clearside Biomedical make?

Clearside Biomedical has a market capitalization of $83.01 million and generates $29.58 million in revenue each year. The company earns $380 thousand in net income (profit) each year or ($0.01) on an earnings per share basis.

How many employees does Clearside Biomedical have?

Clearside Biomedical employs 34 workers across the globe.

What is Clearside Biomedical's official website?

The official website for Clearside Biomedical is www.clearsidebio.com.

How can I contact Clearside Biomedical?

Clearside Biomedical's mailing address is 900 NORTH POINT PARKWAY SUITE 200, ALPHARETTA GA, 30005. The company can be reached via phone at (678) 270-3631, via email at [email protected], or via fax at 678-270-4033.